[go: up one dir, main page]

GB0502083D0 - Bioactive compounds - Google Patents

Bioactive compounds

Info

Publication number
GB0502083D0
GB0502083D0 GBGB0502083.9A GB0502083A GB0502083D0 GB 0502083 D0 GB0502083 D0 GB 0502083D0 GB 0502083 A GB0502083 A GB 0502083A GB 0502083 D0 GB0502083 D0 GB 0502083D0
Authority
GB
United Kingdom
Prior art keywords
bioactive compounds
bioactive
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0502083.9A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aimsco Ltd
Original Assignee
Aimsco Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aimsco Ltd filed Critical Aimsco Ltd
Priority to GBGB0502083.9A priority Critical patent/GB0502083D0/en
Publication of GB0502083D0 publication Critical patent/GB0502083D0/en
Priority to PCT/GB2006/050028 priority patent/WO2006082451A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/695—Corticotropin [ACTH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57509—Corticotropin releasing factor [CRF] (Urotensin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
GBGB0502083.9A 2005-02-02 2005-02-02 Bioactive compounds Ceased GB0502083D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB0502083.9A GB0502083D0 (en) 2005-02-02 2005-02-02 Bioactive compounds
PCT/GB2006/050028 WO2006082451A1 (en) 2005-02-02 2006-02-02 Bioactive compounds

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0502083.9A GB0502083D0 (en) 2005-02-02 2005-02-02 Bioactive compounds

Publications (1)

Publication Number Publication Date
GB0502083D0 true GB0502083D0 (en) 2005-03-09

Family

ID=34307811

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0502083.9A Ceased GB0502083D0 (en) 2005-02-02 2005-02-02 Bioactive compounds

Country Status (2)

Country Link
GB (1) GB0502083D0 (en)
WO (1) WO2006082451A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014130581A1 (en) * 2013-02-20 2014-08-28 Questcor Pharmaceuticals, Inc. Acth for treatment of migraine headache

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1218472B (en) * 1985-08-30 1990-04-19 Alfio Bertolini PHARMACEUTICAL COMPOSITIONS INCLUDING ACHT (1-24) FOR THE THERAPEUTIC TREATMENT OF SHOCK STATES AND RESPIRATORY AND CARDIOCIRCULATORY INSUFFICIENCY
US5714149A (en) * 1989-02-10 1998-02-03 Celltech Therapeutics Limited Crosslinked antibodies and processes for their preparation
DE4110422A1 (en) * 1991-03-29 1992-10-01 Bissendorf Peptide Gmbh MEDICINE CONTAINING HUMANESE CORTICOTROPIN RELEASING HORMON (CRH) AND / OR THEIR DERIVATIVES AND / OR GLUCOCORTICOIDS OF NATURAL AND / OR SYNTHETIC PROVENANCE
AU3489700A (en) * 1999-02-12 2000-08-29 Pharmacal Biotechnologies, Llc Oral compositions and methods of production thereof
CA2452986C (en) * 2001-07-02 2011-11-01 Aimsco Limited Use of polyclonal anti-hiv goat serum as a therapeutic agent
JP2005532261A (en) * 2002-01-28 2005-10-27 エイムスコ・リミテッド Treatment

Also Published As

Publication number Publication date
WO2006082451A1 (en) 2006-08-10

Similar Documents

Publication Publication Date Title
GB0508472D0 (en) Compounds
GB0503962D0 (en) Compounds
GB0507602D0 (en) Compounds
GB0502418D0 (en) Compounds
GB0502316D0 (en) Compounds
AP2007004220A0 (en) Motilide compounds
GB0508463D0 (en) Compounds
EP1907385A4 (en) Compounds
GB0502299D0 (en) Compounds
GB0502310D0 (en) Compounds
GB0505084D0 (en) Compounds
GB0503961D0 (en) Compounds
GB0505086D0 (en) Compounds
GB0506467D0 (en) Compounds
GB0512325D0 (en) Compounds
GB0508460D0 (en) Compounds
GB0505509D0 (en) Compounds
GB0505735D0 (en) Compounds
EP1867650A4 (en) Hydroxymethylboron compounds
GB0501985D0 (en) Compounds
GB0503145D0 (en) Compounds
GB0502083D0 (en) Bioactive compounds
GB0501984D0 (en) Compounds
GB0505085D0 (en) Compounds
GB0503846D0 (en) Compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)